These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19165638)

  • 1. Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy.
    Atkins MB
    Med Oncol; 2009; 26 Suppl 1():18-22. PubMed ID: 19165638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment selection for patients with metastatic renal cell carcinoma.
    Atkins MB; Choueiri TK; Cho D; Regan M; Signoretti S
    Cancer; 2009 May; 115(10 Suppl):2327-33. PubMed ID: 19402069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of metastatic renal cell carcinoma.
    McDermott DF; Atkins MB
    Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
    Dudek AZ; Yee RT; Manivel JC; Isaksson R; Yee HO
    Anticancer Res; 2010 Mar; 30(3):987-92. PubMed ID: 20393025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer.
    Ramsey S
    Mol Diagn Ther; 2009; 13(5):277-81. PubMed ID: 19791832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
    Biswas S; Eisen T
    Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic renal cell cancer treatments.
    Sternberg CN
    Drugs Today (Barc); 2003; 39 Suppl C():39-59. PubMed ID: 14988745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.
    Romo de Vivar Chavez A; de Vera ME; Liang X; Lotze MT
    Med Oncol; 2009; 26 Suppl 1():3-12. PubMed ID: 19148593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
    Rasmussen S; Donskov F; Pedersen JW; Wandall HH; Buus S; Harndahl M; Braendstrup P; Claesson MH; Pedersen AE
    Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):487-96. PubMed ID: 23802595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of metastatic renal cell cancer.
    Fishman M; Seigne J
    Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
    McDermott DF
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for metastatic renal cell carcinoma.
    Wirth MP
    Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
    Atkins M; Regan M; McDermott D; Mier J; Stanbridge E; Youmans A; Febbo P; Upton M; Lechpammer M; Signoretti S
    Clin Cancer Res; 2005 May; 11(10):3714-21. PubMed ID: 15897568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.